Harold J Burstein MD PhD and Lisa A Carey MD on Innovations in Triple Neg BC

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:

•          B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
•          B-51, on radiation to the chest wall
•          Alliance trial, on lymph node dissection

Breast Cancer

Clifford A. Hudis, MD, FACP

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Related Videos

Lisa A. Carey, MD, on the TNT Trial

Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer

William M. Sikov, MD, on the CALGB 40603 Trial

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Clifford A. Hudis, MD, FACP, on the SOFT Trial

HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy

FDA Approves First-Line Pirtobrutinib for CLL-SLL

FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma

FDA Approves New Labeling of ROS1 Inhibitor for NSCLC

Charles Perou 2026 William L. McGuire Memorial Lecture Award